Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 20/20 | 0.73 |
| ▸ | PTGDR | Q13258 | 15/20 | 0.73 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.66 |
| ▸ | PTGFR | P43088 | 1/20 | 0.66 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.66 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.66 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321145 | 0.91 | TBXA2R (0.62) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL12923780 | 0.87 | TBXA2R (0.61) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL3148394 | 0.85 | TBXA2R (0.73) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL991127 | 0.84 | TBXA2R (1.00) | TBXA2RPTGDR | |
| SCHEMBL1254339 | 0.83 | TBXA2R (0.54) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL3974866 | 0.83 | TBXA2R (0.55) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL1255205 | 0.80 | TBXA2R (1.00) | TBXA2RPTGDR | |
| SCHEMBL4548362 | 0.80 | TBXA2R (1.00) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL990454 | 0.78 | TBXA2R (1.00) | TBXA2RPTGDR | |
| SCHEMBL991162 | 0.77 | TBXA2R (1.00) | TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3175856-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS | The Trustees of the University of Pennsylvania (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2037967-B1 | PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR TREATING ANDROGENETIC ALOPECIA | UNIV PENNSYLVANIA (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-12-01 | — | — | US | disclosed |
| US-9254293-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-9254293-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007027532-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006057922-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006052555-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006052798-A2 | METHOD OF TREATING PATHOLOGICAL BLUSHING | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050272756-A1 | Pyridopyrrolizine and pyridoindolizine derivatives | MERCK CANADA INC. (CA) | 2005-12-08 | — | — | US | disclosed |
| EP-1558614-A1 | PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES | Merck Frosst Canada & Co. (CA) | 2005-08-03 | — | — | EP | disclosed |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | CHENG KANG (US) | 2004-11-18 | — | — | US | disclosed |
| WO-2004039807-A1 | PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272756-A1 | Pyridopyrrolizine and pyridoindolizine derivatives | PTGIR, PTGIS, PTGES | TBXA2R 29/4885PTGDR 4/4885PTGER1 6/4885 |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | AR, BPHL, PTGS2 | TBXA2R 888/4885PTGDR 10/4885PTGER1 29/4885 |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | AR, BPHL, PTGS2 | TBXA2R 888/4885PTGDR 10/4885PTGER1 29/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | TBXA2R 434/4885PTGDR 509/4885PTGER1 258/4885 |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | TBXA2R 37/4885PTGDR 201/4885PTGER1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.